ATOPIC-DERMATITIS

DERMATOLOGY

Atopic Dermatitis Control Tool (ADCT)

Numerical Rating Scale (NRS)

quadrivalent influenza vaccine (recombinant, prepared in cell culture)

INFLUENZA

VACCINES

Supemtek

GAUCHER

RARE-DISEASE

CERDELGA®

split virion, inactivated. Suspension for injection in pre-filled syringe

Quadrivalent Influenza Vaccine

MULTIPLE-SCLEROSIS

NEUROLOGY

Lemtrada® - Coming Soon

hepatitis A vaccine (inactivated, adsorbed)

TRAVEL

HEPATITIS-A

AVAXIM®&nbsp;JUNIOR

DYSLIPIDEMIA

CARDIOLOGY

Praluent®

diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and haemophilus type b conjugate vaccine (adsorbed)

ACELLULAR-PERTUSSIS

POLIO

DIPHTERIA-TETANUS-BOOSTER

HEPATITIS-B

TETANUS-BOOSTER

DTACP-HIB-IPV-HEP-B-HEXA-ACELLULAR-PRIMARY-SERIES

DIPHTHERIA

HAEMOPHILUS-INFLUENZA

TETANUS

VAXELIS®

diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)

DTACP-HIB-IPV-PENTA-ACELLULAR-PRIMARY-SERIES

TDACP-IPV-BOOSTER

REPEVAX®

diphtheria, tetanus & poliomyelitis (inactivated) vaccine (absorbed, reduced antigen(s) content)

TD-IPV-BOOSTER

REVAXIS®

CEREZYME®

POMPE

MYOZYME®

MULTIPLE-MYELOMA

ONCOLOGY

SARCLISA®

TRANSPLANT

REZUROCK®&nbsp;

TYPE-2-DIABETES

TYPE-1-DIABETES

DIABETES

Lantus®

RABIES

Verorab®

ADMELOG®

Split Virion, Inactivated High-Dose (QIV-HD)

Quadrivalent Influenza Vaccine (QIV-HD)

TOUJEO®

Trurapi®

TYPHOID

TYPHIM Vi®

AVAXIM®

FABRY

Fabrazyme®

meningococcal (group A,C,W,Y) conjugate vaccine

MENINGOCOCCAL-DISEASE

MenQuadfiTM

CERDELGA®

Achieve lasting change with DUPIXENT (dupilumab). Read about DUPIXENT in AD.

PRURIGO-NODULARIS

DUPIXENT®&nbsp;Atopic Dermatitis

YELLOW-FEVER

STAMARIL®

Hepatitis A (inactivated, adsorbed) and Typhoid polysaccharide vaccine

Viatim®

THROMBOSIS

<div>
 Clexane®
</div>

Nexviadyme®&nbsp;

MUCOPOLYSACCHARIDOSIS-MPS

Aldurazyme®&nbsp;

Achieve a lasting change with DUPIXENT (dupilumab). Read about DUPIXENT in PN.

DUPIXENT®&nbsp;Prurigo Nodularis

MyPraluent® (alirocumab) COACH

Praluent® (alirocumab) - Comprehensive Support for the Praluent® Patient

PAYOR

OUT-OF-TAXONOMY

Health System Collaboration Portal

Rabies Support Materials 

Website with information for patients prescribed Nexviadyme

Nexviadyme▼ (avalglucosidase alfa) website

Cerdelga▼ (eliglustat) Patient Materials

Formulary and Service Support

Helping your patients understand their treatment

Praluent® (alirocumab) Patient profiles

Diagnostic Algorithms for Gaucher disease

Let’s be Collaborative​ and Transformative

Praluent® (alirocumab) Homecare Services

Praluent® (alirocumab) Patient Resources

Hot Topics in Atopic Dermatitis

Dupixent (dupilumab) Resources

Patient Organisation Website

OTHER-VACCINES-TOPICS

Ways to Order

A short animation to support your patient discussions on herd immunity for flu, and why flu vaccination is important to help protect them, their loved ones and their communities.

Herd immunity for flu

Hepatitis A Booster Campaigns

DUPIXENT® (dupilumab) Atopic Dermatitis Patient Support Resources

OTHER-RARE-DISEASE-TOPICS

Dietician Resources for patients with Rare Diseases

Let’s Be Sustainable

Diabetes patient support

Downloadable PDF: Signs & Symptoms of Gaucher disease

Hajj & Umrah 2024

EBMT 2024: The late effects of chronic GvHD: The challenge of long-term management

EBMT 2024: QoL and chronic GvHD

Diabetes UK 2023:
Multifactorial approach to diabetes management

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Diabetes UK 2024:
Connecting the Dots: Benefits of pen connectivity for people living with diabetes

HEART UK

Paradigm 2024:
Ketan Dhatariya 

Vaccines Education and Training

Diabetes UK 2023: Cultural humility in diabetes consultation

Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients

EBMT 2024: Treatment of steroid refractory chronic GvHD

Paradigm 2024:
Lesley Mills

For nurses and allied healthcare professionals with an interest in chronic GvHD

InTen Nurse Forum - ACCEND Framework

Diabetes UK 2024:
Navigating Hyperglycaemia after GLP-1s with Insulin

The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS

Promotional podcasts on a variety of different topics and meetings that have been organised and funded by Sanofi

Diabetes Podcast Series | Toujeo® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL) 

EBMT 2024: Frontline treatment of chronic GvHD

InTen Nurse Forum: What is chronic GvHD?

What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes

EBMT 2024: Roundtable: Exploring clinical cases

Diabetes UK 2024:
Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot

Strengthening the Interface Between Primary and Secondary Care

Ask us your questions about our products, patient materials or organising a meeting.

Sanofi is here to support you and your patients

<h3>Toujeo® DoubleStar™ 
 (insulin glargine 300 units/mL)</h3>
<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information</a>

<h3>Toujeo® SoloStar™ 
 (insulin glargine 300 units/mL)</h3>
<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information</a>

<h3>Lantus® SoloStar™ 
 (insulin glargine 100 units/mL)</h3>
<a href="${link:{uuid:{8f132346-a5c2-470d-8368-64ab56220e08},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI_PI.pdf}}}">Prescribing information</a>

<h3>Admelog® 
 (insulin lispro 100 units/mL)</h3>
<h3>This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.</h3>

<h3>Trurapi®▼ 
 (insulin aspart 100 units/mL)</h3>
<h3>This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.</h3>

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Type 2 Diabetes

Latest Resources

Diabetes patient support